Therapies in HIV infection
Zangerle, R.
Wiener Medizinische Wochenschrift 148(23-24): 525-526
1998
ISSN/ISBN: 0043-5341 PMID: 10189680 Document Number: 486934
Document emailed within 1 workday
Related Documents
Katzenstein, D. 1997: Combination therapies for HIV infection and genomic drug resistance Lancet 350(9083): 970-971McCaughan, G.W.; Strasser, S.I. 2000: Emerging therapies for hepatitis C virus (HCV) infection: the importance of HCV genotype Australian and New Zealand Journal of Medicine 30(6): 644-646
Rotella, D. 2001: 221st ACS. Division of Medicinal Chemistry - inhibitors of HIV entry: potential new therapies for treatment of HIV infection Idrugs: the Investigational Drugs Journal 4(6): 629-630
Gotoh, M. 2009: Treatment and rehabilitation programs for young alcoholics: acquiring the ability through group therapies and cognitive-behavioral therapies to communicate with others to lead a new life Nihon Arukoru Yakubutsu Igakkai Zasshi 44(5): 579-603
Roy, S.; Wilkins, J.; March, C.M.; Solera, N.C.; Galvan, N.I.; Ressler, R.L.; Cendejas, K.A.; Neal, J.; Azen, C.G.; Essin, D.J. 1990: A comparison of the efficacy and safety of ceftizoxime with doxycycline versus conventional CDC therapies in the treatment of upper genital tract infection with or without a mass Clinical Therapeutics 12(Suppl): 53-73
Campbell, R.K.; Cobble, M.E.; Reid, T.S.; Shomali, M.E. 2010: Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies Journal of Family Practice 59(9 Suppl 1: S20-S27
Cabie, A.; Matheron, S.; Lepretre, A.; Bouchaud, O.; Deluol, A.M.; Coulaud, J.P. 1992: Leishmaniose viscérale au cours de l'infection par le VIH : une infection opportuniste à part entière - Visceral leishmaniasis and HIV infection. A fully opportunistic infection la Presse Medicale (1983) 21(35): 1658-1662
Cabie, A.; Matheron, S.; Lepretre, A.; Bouchaud, O.; Deluol, A.M.; Coulaud, J.P. 1992: Leishmaniose viscérale au cours de l'infection par le VIH : une infection opportuniste à part entière - Visceral leishmaniasis and HIV infection. A fully opportunistic infection la Presse Medicale (1983) 21(35): 1658-1662
Bellido Guerrero, D.; Carreira Arias, J. 1994: New therapies in obesity Revista Clinica Espanola 194(8): 636-646
Olié, J.P.; Baylé, F.J. 1996: New drug therapies L'Encephale 22(Special Issue 3): 63-71; Discussion 76
Barker, P. 1998: The behavioural therapies Nursing Times 94(10): 44-46
Araki, M. 1970: Various oxygen therapies Nursing Technique 5: 117-121
Millikan, L.E. 1999: Anecdotal therapies Advances in Experimental Medicine and Biology 455: 407-411
Davis, S.R. 2003: Menopause: new therapies Medical Journal of Australia 178(12): 634-637
Lipozecić, J.; Pasić, A.; Wolf, R. 2004: Update on psoriasis therapies Acta Dermatovenerologica Croatica: Adc 12(1): 35-41
Buckle, J. 1992: Which lavender oil? Complementary therapies Nursing Times 88(32): 54-55
Benca, R.M. 2001: Consequences of insomnia and its therapies Journal of Clinical Psychiatry 62(Suppl): 33-38
Nally, J.B.; Berson, D.S. 2006: Topical therapies for rosacea Journal of Drugs in Dermatology: Jdd 5(1): 23-26
Dibner, M.D.; Ackerman, N.R. 1986: Biotechnology and new therapies for arthritis Journal of Rheumatology 13(6): 997-999
McOrist, S.; Uche, U.E.; Lloyd, B.R. 2001: Inappropriate use of alternative therapies Veterinary Record 149(14): 432